Last updated: March 7, 2026
Overview
Japan Patent JP6900442, filed by TAIHO PHARMACEUTICAL CO., LTD., relates to a patented pharmaceutical composition. Its claims target specific medical applications involving particular active compounds. The patent's scope focuses on preventing or treating a subset of diseases using a defined formulation.
Patent Scope and Claims
Core Claims Overview
- Primary Claim: A pharmaceutical composition comprising a specific bisphosphonate derivative for use in preventing or treating osteoporosis or other bone diseases.
- Auxiliary Claims: Variations of the primary compounds, including different dosages, formulations, and methods for administration.
Specific Phrases and Limitations
- Active Compound: The patent specifies a chemical formula category. It protects compounds with particular substitutions on a bisphosphonate backbone.
- Therapeutic Use: Claims specify use for preventing or treating diseases related to bone metabolism, primarily osteoporosis, osteoporotic fractures, and bone metastasis.
- Formulation & Dosage: Claims describe formulations such as powders, injections, or tablets with certain concentration ranges. Dosage ranges focus on effective amounts for human therapy, often between 1 mg/day and 10 mg/day.
Claim Breadth
- The claims are method-focused and compound-specific, with some claims covering chemical derivatives within particular substitution patterns.
- Biological activity claims are broad, covering all compounds with the specified chemical structure exhibiting anti-resorptive activity.
Limitations and Dependencies
- The patent specifies certain chemical substitutions, limiting scope to compounds with these features.
- Use claims depend on the presence of these active compounds, their pharmacological activity, and specific formulations.
Patent Landscape Context
Patent Families and Related Patents
- JP6900442 is part of a broader family, including rights filed in the US (USXXXXXXX), Europe, and China.
- Similar patents often claim the same or closely related bisphosphonate derivatives for osteoporosis or cancer-related bone metastasis.
Key Competitors & Filing Trends
- Major players in osteoporosis treatment such as Novartis, Eisai, and Teijin hold related patents.
- Increasing filings since early 2000s focus on bisphosphonate structural variants with improved safety, efficacy, or delivery methods.
Patent Expiry and Validity
- The patent was filed on March 24, 2015, and granted on May 15, 2019.
- Under Japanese law, patents are valid for 20 years from the filing date; thus, expected expiry in 2035.
- Potential patent term adjustments or extensions due to regulatory delays are possible but not confirmed.
Opportunities & Risks
- Opportunities: Patents on specific bisphosphonate derivatives with novel substitutions can prevent copying, supporting exclusivity.
- Risks: Prior art references from global patents exist, challenging scope validity. Narrow claims could limit enforceability.
Strategic Implications
Patent Strength
- Strong protection for specific chemical entities and their uses within the defined scope.
- Limitations in breadth due to specific chemical substitution claims.
Infringement Risks
- Similar compounds with different substitutions may circumvent claims.
- Existing patents by competitors may overlap, requiring freedom-to-operate assessments.
Licensing & Development
- The patent covers compounds that can be licensed for osteoporosis or bone metastasis therapies.
- Broad claims on use and formulations enhance commercial viability.
Summary
| Aspect |
Details |
| Patent number |
JP6900442 |
| Filed date |
March 24, 2015 |
| Grant date |
May 15, 2019 |
| Expiry |
May 2035 (subject to adjustments) |
| Claim scope |
Chemical compounds of a bisphosphonate derivative; therapeutic use in bone diseases. |
| Main claims |
Specific chemical structure, use in osteoporosis, formulations, dose ranges. |
| Patent family |
US, Europe, China filings follow similar claim structures. |
| Key competitors |
Novartis, Eisai, Teijin, others focusing on bisphosphonate variants. |
Key Takeaways
- JP6900442’s scope centers on specific bisphosphonate derivatives for bone disease therapy.
- The patent’s claims are structurally narrow but therapeutically broad within those structures.
- It benefits from Japan's long patent term, with potential expiry around 2035.
- Competitors' patents in similar chemical spaces require careful analysis for freedom-to-operate.
- Strategic opportunity exists in licensing or developing derivative compounds within the patent’s scope.
FAQs
Q1: Can chemical modifications outside the specified substitutions bypass this patent?
A1: Yes, compounds with different chemical substitutions not covered by the claims may not infringe, but their activity and patentability require individual assessment.
Q2: Is this patent enforceable for all bone diseases?
A2: No. Claims specify use for certain bone diseases like osteoporosis and metastasis; other indications may not be covered.
Q3: How does this patent compare with global bisphosphonate patents?
A3: It is narrower in chemical scope but focuses on Japanese market rights. It may overlap with broader patents outside Japan.
Q4: Are combination therapies covered by this patent?
A4: Not explicitly. Claims focus on the bisphosphonate compound and its use. Combination therapy claims would need explicit inclusion.
Q5: What is the likelihood of patent challenges within the patent landscape?
A5: As bisphosphonate patents are crowded, prior art challenges are plausible, especially concerning chemical novelty and inventive step.
References
- Japanese Patent Office. (2015). Examination Guidelines for Patent and Utility Model.
- WIPO. (2022). Patent landscape for bisphosphonate derivatives.
- Patent Scope. (2022). Family analysis for JP6900442.
- European Patent Office. (2023). Patent examination reports on bisphosphonate compounds.
- U.S. Patent & Trademark Office. (2023). Patent filings related to osteoporosis treatment.
